The international, multicenter, open-label, randomized phase 3 MURANO study included a total of 389 patients with R/R CLL who had received at least one prior therapy.
The primary endpoint was progression-free survival of venetoclax in combination with rituximab for up to two years compared with bendamustine in combination with rituximab for six months.
Of the 121 patients who achieved uMRD at the end of combination therapy, 83% maintained uMRD and were progression-free for a median of 13.8 months thereafter.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for complex and critical conditions.
The company's mission is to improve treatments across four primary therapeutic areas: immunology, oncology, virology, and neuroscience.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886